What Is CRB-913, and Why Does Its September Trial Readout Matter?

What Is CRB-913?

CRB-913 is an investigational, once-daily oral small molecule developed by Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP). It works as a CB1 (cannabinoid receptor type 1) inverse agonist — a mechanism that pushes activity at the CB1 receptor below its normal resting level, producing effects broadly opposite to cannabinoid stimulation of appetite and reward pathways. Unlike semaglutide, tirzepatide or retatrutide, CRB-913 does not target the GLP-1, GIP or glucagon receptors at all; it works through an entirely separate appetite-regulation pathway in the endocannabinoid system.[1]

The company describes CRB-913 as "highly peripherally restricted," meaning it is deliberately engineered to minimise crossing of the blood-brain barrier — a design choice that exists specifically to avoid the central-nervous-system side effects that ended the first generation of CB1-targeted obesity drugs (see below). CRB-913 is an unlicensed investigational compound with no approved indication anywhere; it is not a research peptide and is not related to any compound sold by Velox Peptides.

Why Did Earlier CB1 Obesity Drugs Fail?

CB1 inverse agonists are not a new idea. Sanofi-Aventis's rimonabant (marketed in Europe as Acomplia) was approved by the EMA in June 2006 as a weight-management treatment. In October 2008, following a review of post-marketing safety data showing roughly double the risk of psychiatric adverse events — including depression and suicidal ideation — versus placebo, the EMEA recommended suspending its marketing authorisation; the drug was formally withdrawn in January 2009. The FDA never approved rimonabant, having already rejected it in 2007 over the same psychiatric safety signal.[2]

A 2024 reassessment of rimonabant's clinical trial database in the journal Obesity revisited the original suicidality signal in detail, underscoring how central this single safety question remains to any company now re-entering the CB1 mechanism.[3]

What Did the Phase 1a Data Show?

Reporting Phase 1a results on 11 December 2025, Corbus described a favourable safety profile across escalating once-daily doses along with early signs of weight loss, and cited preclinical data showing roughly 15-fold lower brain penetration than the CB1 inverse agonist monlunabant, and a brain-to-plasma ratio around 50-fold lower than rimonabant.[1] Phase 1a is a small, early-stage safety study; it does not establish efficacy in the way a larger, placebo-controlled obesity trial does, which is what CANYON-1 is designed to test.

What Is the CANYON-1 Phase 1b Trial Testing?

CANYON-1 (NCT07310901) is a 16-week, double-blind, placebo-controlled, dose-ranging Phase 1b trial conducted at multiple US sites in 240 obese, non-diabetic adults. Participants were randomised to placebo or one of three CRB-913 dose cohorts — 20mg, 40mg or 60mg, taken orally once daily — with all active-arm participants starting at 20mg/day and titrating up to their assigned dose. Treatment runs for 12 weeks, followed by a four-week safety follow-up period.[4]

As a Phase 1b study, CANYON-1's primary purpose is to establish safety, tolerability and pharmacokinetics across the dose range, with body-weight change as a secondary measure. It is not a pivotal Phase 3 trial, and any weight-loss data it produces will need replication in larger, longer studies before it says much about how CRB-913 might eventually compare with approved obesity treatments.

When and How Will Results Be Announced?

Corbus announced Last Patient Last Visit in CANYON-1 on 4 August 2026, and on 11 September 2026 confirmed it will host a conference call and webcast on Monday, 14 September 2026 at 8:00am EDT to discuss topline data from the trial and management's view of CRB-913's potential in obesity.[5] As of this article's publication (13 September 2026), the topline results themselves have not yet been made public.

How Does a CB1 Inverse Agonist Differ From GLP-1-Class Compounds Like Retatrutide?

Retatrutide, tirzepatide and semaglutide all work by activating incretin-pathway receptors (GLP-1, GIP and, in retatrutide's case, glucagon) to reduce appetite and increase energy expenditure. CRB-913 works upstream of that system entirely, modulating CB1 receptor tone in the endocannabinoid system instead. If a peripherally restricted CB1 inverse agonist can be shown to be both effective and free of the psychiatric liability that ended rimonabant, it would represent a genuinely distinct, non-incretin mechanism for weight management — part of a broader industry trend toward diversifying beyond the GLP-1 class that also includes oral small-molecule GLP-1 agonists such as AstraZeneca's elecoglipron.[6] See our guide on retatrutide's mechanism of action for how the incretin pathway compares.

It is far too early to draw comparisons on efficacy or safety between CRB-913 and any incretin-class compound: CANYON-1 is a 240-patient, 16-week Phase 1b study, while retatrutide's TRIUMPH-1 programme, for comparison, enrolled over 2,300 patients across 80 weeks. CRB-913 has not been studied head-to-head against any GLP-1-class drug.

Does This Affect Research-Reagent Supply or Retatrutide's Regulatory Status?

No. CRB-913 is a small-molecule drug candidate from a separate, publicly traded pharmaceutical company running its own IND-stage clinical programme in the United States. It has no bearing on the UK regulatory position for research reagents under the Human Medicines Regulations 2012 — see our guide on whether research peptides are legal in the UK — nor on Eli Lilly's separate retatrutide filing timeline. Retatrutide remains unlicensed for human use everywhere and continues to be supplied by Velox Peptides only as an HPLC-verified in vitro laboratory reagent.

Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions